195 related articles for article (PubMed ID: 24461710)
1. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.
Pistiki A; Galani I; Pyleris E; Barbatzas C; Pimentel M; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2014 Mar; 43(3):236-41. PubMed ID: 24461710
[TBL] [Abstract][Full Text] [Related]
2. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations.
Debbia EA; Maioli E; Roveta S; Marchese A
J Chemother; 2008 Apr; 20(2):186-94. PubMed ID: 18467244
[TBL] [Abstract][Full Text] [Related]
3. Review of rifaximin as treatment for SIBO and IBS.
Pimentel M
Expert Opin Investig Drugs; 2009 Mar; 18(3):349-58. PubMed ID: 19243285
[TBL] [Abstract][Full Text] [Related]
4. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Majewski M; McCallum RW
Adv Med Sci; 2007; 52():139-42. PubMed ID: 18217406
[TBL] [Abstract][Full Text] [Related]
5. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.
Triantafyllou K; Sioulas AD; Giamarellos-Bourboulis EJ
Mini Rev Med Chem; 2015; 16(3):186-92. PubMed ID: 26202193
[TBL] [Abstract][Full Text] [Related]
7. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
8. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
Moraru IG; Moraru AG; Andrei M; Iordache T; Drug V; Diculescu M; Portincasa P; Dumitrascu DL
Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome.
Pyleris E; Giamarellos-Bourboulis EJ; Tzivras D; Koussoulas V; Barbatzas C; Pimentel M
Dig Dis Sci; 2012 May; 57(5):1321-9. PubMed ID: 22262197
[TBL] [Abstract][Full Text] [Related]
10. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.
Cuoco L; Salvagnini M
Minerva Gastroenterol Dietol; 2006 Mar; 52(1):89-95. PubMed ID: 16554709
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?
Farrell DJ
J Clin Gastroenterol; 2013 Mar; 47(3):205-11. PubMed ID: 23340064
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin treatment for symptoms of irritable bowel syndrome.
Fumi AL; Trexler K
Ann Pharmacother; 2008 Mar; 42(3):408-12. PubMed ID: 18303148
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).
Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Feb; 69(2):223-7. PubMed ID: 21251571
[TBL] [Abstract][Full Text] [Related]
14. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
15. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.
Scarpignato C; Pelosini I
Chemotherapy; 2005; 51 Suppl 1():36-66. PubMed ID: 15855748
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center in Taiwan: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2002-2006.
Chen WY; Jang TN; Huang CH; Hsueh PR
J Microbiol Immunol Infect; 2009 Aug; 42(4):317-23. PubMed ID: 19949755
[TBL] [Abstract][Full Text] [Related]
18. The effect of rifaximin on gut flora and Staphylococcus resistance.
Kim MS; Morales W; Hani AA; Kim S; Kim G; Weitsman S; Chang C; Pimentel M
Dig Dis Sci; 2013 Jun; 58(6):1676-82. PubMed ID: 23589147
[TBL] [Abstract][Full Text] [Related]
19. Detection of High-Level Rifaximin Resistance in Enteric Bacteria by Agar Screen.
Baumert PMP; Camp J; Gölz H; Vavra M; Schuster S; Kern WV; Mischnik A;
Microb Drug Resist; 2020 Jun; 26(6):545-549. PubMed ID: 31855490
[No Abstract] [Full Text] [Related]
20. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.
Hoover WW; Gerlach EH; Hoban DJ; Eliopoulos GM; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):111-8. PubMed ID: 8385592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
